熱門資訊> 正文

Solid Biosciences将AAV-SLB 101许可证授予Kamar Bio

2025-09-23 21:41

Solid Biosciences (NASDAQ:SLDB) has entered into a collaboration with Kinea Bio, granting them a non-exclusive worldwide license to use Solid’s AAV-SLB101 capsid.
This partnership focuses on the development and commercialization of KNA-155 using AAV-SLB101, for the treatment of dysferlinopathy, a type of limb-girdle muscular dystrophy.
Under the deal, Solid Biosciences will receive an upfront payment and may earn additional payments as Kinea Bio meets specific development and sales milestones, along with tiered royalties based on net sales.

More on Solid Biosciences

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)
Solid Biosciences GAAP EPS of -$0.42 beats by $0.09
Solid Biosciences gets FDA fast track status for heart disease therapy
Seeking Alpha’s Quant Rating on Solid Biosciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。